<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32111867</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration.</ArticleTitle><Pagination><StartPage>3715</StartPage><MedlinePgn>3715</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3715</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-60431-6</ELocationID><Abstract><AbstractText>0.5-1% of ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease (PD) are associated with mutations in the angiogenin (ANG). These mutations are thought to cause disease through a loss of ANG function, but this hypothesis has not been evaluated statistically. In addition, the potential for ANG to promote disease has not been considered. With the goal of better defining the etiology of ANG-ALS, we assembled all clinical onset and disease duration data and determined if these were correlated with biochemical properties of ANG variants. Loss of ANG stability and ribonuclease activity were found to correlate with early ALS onset, confirming an aspect of the prevailing model of ANG-ALS. Conversely, loss of ANG stability and ribonuclease activity correlated with longer survival following diagnosis, which is inconsistent with the prevailing model. These results indicate that functional ANG appears to decrease the risk of developing ALS but exacerbate ALS once in progress. These findings are rationalized in terms of studies demonstrating that distinct mechanisms contribute to ALS onset and progression and propose that ANG replacement or stabilization would benefit pre-symptomatic ANG-ALS patients. However, this study challenges the prevailing hypothesis that augmenting ANG will benefit symptomatic ANG-ALS patients. Instead, our results suggest that silencing of ANG activity may be beneficial for symptomatic ALS patients. This study will serve as a call-to-arms for neurologists to consistently publish ALS and PD patient's clinical data-if all ANG-ALS patients' data were available our findings could be tested with considerable statistical power.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aluri</LastName><ForeName>Krishna C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-7460-8727</Identifier><AffiliationInfo><Affiliation>Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts, 02115, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salisbury</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-9448-9024</Identifier><AffiliationInfo><Affiliation>Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts, 02115, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prehn</LastName><ForeName>Jochen H M</ForeName><Initials>JHM</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, SFI Future-Neuro Centre, Royal College of Surgeons in Ireland, Dublin, 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agar</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA, 02115, USA. j.agar@northeastern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts, 02115, United States. j.agar@northeastern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts, 02115, United States. j.agar@northeastern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS065263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.27.-</RegistryNumber><NameOfSubstance UI="C046366">angiogenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.27.5</RegistryNumber><NameOfSubstance UI="D012259">Ribonuclease, Pancreatic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073658" MajorTopicYN="Y">Loss of Function Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012259" MajorTopicYN="N">Ribonuclease, Pancreatic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013534" MajorTopicYN="N">Survival</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.P. is a beneficiary of patents relating to the use of angiogenin for the treatment of CNS diseases. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32111867</ArticleId><ArticleId IdType="pmc">PMC7048737</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-60431-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-60431-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-31750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-31750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur. J. Neurol. 2007;14:262&#x2013;268. doi: 10.1111/j.1468-1331.2006.01575.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01575.x</ArticleId><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R. FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows Progression. Neurol. Today. 2017;17:1&#x2013;30.</Citation></Reference><Reference><Citation>Greenway, M. J. et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology63, 1936&#x2013;1938, doi:63/10/1936 [pii] (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15557516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M-L, Wu R-M, Tai C-H, Lin C-H. Mutational analysis of angiogenin gene in Parkinson&#x2019;s disease. PLoS one. 2014;9:e112661. doi: 10.1371/journal.pone.0112661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112661</ArticleId><ArticleId IdType="pmc">PMC4227694</ArticleId><ArticleId IdType="pubmed">25386690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji T, et al. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res. 2005;65:1352&#x2013;1360. doi: 10.1158/0008-5472.CAN-04-2058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-2058</ArticleId><ArticleId IdType="pubmed">15735021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuazo-Gaztelu I, Casanovas O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front. Oncol. 2018;8:248. doi: 10.3389/fonc.2018.00248.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00248</ArticleId><ArticleId IdType="pmc">PMC6036108</ArticleId><ArticleId IdType="pubmed">30013950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J, Xu Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim. Biophys. Sin. 2016;48:399&#x2013;410. doi: 10.1093/abbs/gmv131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmv131</ArticleId><ArticleId IdType="pmc">PMC4888354</ArticleId><ArticleId IdType="pubmed">26705141</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree B, et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochem. 2007;46:11810&#x2013;11818. doi: 10.1021/bi701333h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi701333h</ArticleId><ArticleId IdType="pubmed">17900154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw WJ, et al. Structural insights into human angiogenin variants implicated in Parkinson&#x2019;s disease and Amyotrophic Lateral Sclerosis. Sci. Rep. 2017;7:41996. doi: 10.1038/srep41996srep41996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41996srep41996</ArticleId><ArticleId IdType="pmc">PMC5296752</ArticleId><ArticleId IdType="pubmed">28176817</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparicio-Erriu IM, Prehn JH. Molecular Mechanisms in Amyotrophic Lateral Sclerosis: The Role of Angiogenin, a Secreted RNase. Front. Neurosci. 2012;6:167. doi: 10.3389/fnins.2012.00167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00167</ArticleId><ArticleId IdType="pmc">PMC3500830</ArticleId><ArticleId IdType="pubmed">23181008</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian V, Feng Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 2007;16:1445&#x2013;1453. doi: 10.1093/hmg/ddm095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm095</ArticleId><ArticleId IdType="pubmed">17468498</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian V, Crabtree B, Acharya KR. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum. Mol. Genet. 2008;17:130&#x2013;149. doi: 10.1093/hmg/ddm290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm290</ArticleId><ArticleId IdType="pubmed">17916583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, et al. Control of motoneuron survival by angiogenin. J. Neurosci. 2008;28:14056&#x2013;14061. doi: 10.1523/JNEUROSCI.3399-08.200828/52/14056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3399-08.200828/52/14056</ArticleId><ArticleId IdType="pmc">PMC6671464</ArticleId><ArticleId IdType="pubmed">19109488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 2007;62:609&#x2013;617. doi: 10.1002/ana.21221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21221</ArticleId><ArticleId IdType="pmc">PMC2776820</ArticleId><ArticleId IdType="pubmed">17886298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishikawa H, Wu D, Hu GF. Targeting angiogenin in therapy of amyotropic lateral sclerosis. Expert. Opin. Ther. Targets. 2008;12:1229&#x2013;1242. doi: 10.1517/14728222.12.10.1229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.12.10.1229</ArticleId><ArticleId IdType="pmc">PMC2782700</ArticleId><ArticleId IdType="pubmed">18781822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Johnson JL, Agar NY, Agar JN. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 2008;6:e170. doi: 10.1371/journal.pbio.006017008-PLBI-RA-0487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.006017008-PLBI-RA-0487</ArticleId><ArticleId IdType="pmc">PMC2486295</ArticleId><ArticleId IdType="pubmed">18666828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratovitski T, et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum. Mol. Genet. 1999;8:1451&#x2013;1460. doi: 10.1093/hmg/8.8.1451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.8.1451</ArticleId><ArticleId IdType="pubmed">10400992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt AJ, et al. Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc. Natl Acad. Sci. USA. 2014;111:E4568&#x2013;4576. doi: 10.1073/pnas.1308531111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308531111</ArticleId><ArticleId IdType="pmc">PMC4217430</ArticleId><ArticleId IdType="pubmed">25316790</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin JA, et al. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc. Natl Acad. Sci. USA. 2014;111:4309&#x2013;4314. doi: 10.1073/pnas.1317317111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317317111</ArticleId><ArticleId IdType="pmc">PMC3964094</ArticleId><ArticleId IdType="pubmed">24591609</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl Acad. Sci. USA. 1994;91:8292&#x2013;8296. doi: 10.1073/pnas.91.17.8292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.17.8292</ArticleId><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdolvahabi A, et al. Kaplan-Meier Meets Chemical Kinetics: Intrinsic Rate of SOD1 Amyloidogenesis Decreased by Subset of ALS Mutations and Cannot Fully Explain Age of Disease Onset. ACS Chem. Neurosci. 2017;8:1378&#x2013;1389. doi: 10.1021/acschemneuro.7b00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00029</ArticleId><ArticleId IdType="pubmed">28290665</ArticleId></ArticleIdList></Reference><Reference><Citation>Belli M, Ramazzotti M, Chiti F. Prediction of amyloid aggregation in vivo. EMBO Rep. 2011;12:657&#x2013;663. doi: 10.1038/embor.2011.116embor2011116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2011.116embor2011116</ArticleId><ArticleId IdType="pmc">PMC3128957</ArticleId><ArticleId IdType="pubmed">21681200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006;75:333&#x2013;366. doi: 10.1146/annurev.biochem.75.101304.123901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.123901</ArticleId><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D, et al. Physicochemical characteristics of soluble oligomeric A &#x3b2; and their pathologic role in Alzheimer&#x2019;s disease. Neurological Res. 2005;27:869&#x2013;881. doi: 10.1179/016164105X49436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164105X49436</ArticleId><ArticleId IdType="pubmed">16354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedde KN, Michell MP, Henthorn PS, Whyte MP. Aberrant properties of alkaline phosphatase in patient fibroblasts correlate with clinical expressivity in severe forms of hypophosphatasia. J. Clin. Endocrinol. Metab. 1996;81:2587&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8675582</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both &#x3b1;-synuclein mutations linked to early-onset Parkinson&#x2019;s disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. 2000;97:571&#x2013;576. doi: 10.1073/pnas.97.2.571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.2.571</ArticleId><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot NS, Aviles FX, Vendrell J, Ventura S. Mutagenesis of the central hydrophobic cluster in A&#x3b2;42 Alzheimer&#x2019;s peptide: Side&#x2010;chain properties correlate with aggregation propensities. FEBS J. 2006;273:658&#x2013;668. doi: 10.1111/j.1742-4658.2005.05102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2005.05102.x</ArticleId><ArticleId IdType="pubmed">16420488</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem. 2013;288:3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham AD, Colavin A, Huang KC, Mochly-Rosen D. Coupling between Protein Stability and Catalytic Activity Determines Pathogenicity of G6PD Variants. Cell Rep. 2017;18:2592&#x2013;2599. doi: 10.1016/j.celrep.2017.02.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.02.048</ArticleId><ArticleId IdType="pmc">PMC5396575</ArticleId><ArticleId IdType="pubmed">28297664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R, Wai-Ling Butler A, Andersen PM, Powell JF, Al-Chalabi A. ALSOD: the Amyotrophic Lateral Sclerosis Online Database. Amyotroph. Lateral Scler. 2008;9:249&#x2013;250. doi: 10.1080/17482960802146106793701370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802146106793701370</ArticleId><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, et al. A mutation database for amyotrophic lateral sclerosis. Hum. Mutat. 2010;31:1003&#x2013;1010. doi: 10.1002/humu.21306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21306</ArticleId><ArticleId IdType="pubmed">20556799</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiyagarajan N, Ferguson R, Subramanian V, Acharya KR. Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat. Commun. 2012;3:1121. doi: 10.1038/ncomms2126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2126</ArticleId><ArticleId IdType="pmc">PMC3493651</ArticleId><ArticleId IdType="pubmed">23047679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples) Biometrika. 1965;52:591&#x2013;611. doi: 10.1093/biomet/52.3-4.591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/52.3-4.591</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman C. The Proof and Measurement of Association between Two Things. Am. J. Psychol. 1904;15:72&#x2013;101. doi: 10.2307/1412159.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1412159</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendall MG. A New Measure of Rank Correlation. Biometrika. 1938;30:81&#x2013;93. doi: 10.2307/2332226.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2332226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst. Monogr. 1961;6:101&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">13889176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966;50:163&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">5910392</ArticleId></ArticleIdList></Reference><Reference><Citation>TARONE ROBERT E., WARE JAMES. On distribution-free tests for equality of survival distributions. Biometrika. 1977;64(1):156&#x2013;160. doi: 10.1093/biomet/64.1.156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/64.1.156</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow, N. E. &amp; Day, N. E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ, 5&#x2013;338 (1980).</Citation><ArticleIdList><ArticleId IdType="pubmed">7216345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression Models and Life-Tables. J. R. Stat. Society. Ser. B. 1972;34:187&#x2013;220.</Citation></Reference><Reference><Citation>Zwiener I, Blettner M, Hommel G. Survival analysis: part 15 of a series on evaluation of scientific publications. Dtsch. &#xc4;rzteblatt Int. 2011;108:163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071962</ArticleId><ArticleId IdType="pubmed">21475574</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi AK, Jayaram B, Gomes J. Prediction of Functional Loss of Human Angiogenin Mutants Associated with ALS by Molecular Dynamics Simulations. Sci. Rep. 2013;3:1225. doi: 10.1038/srep01225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01225</ArticleId><ArticleId IdType="pmc">PMC3566597</ArticleId><ArticleId IdType="pubmed">23393617</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivello M, et al. Pleiotropic activity of systemically delivered angiogenin in the SOD1(G93A) mouse model. Neuropharmacol. 2018;133:503&#x2013;511. doi: 10.1016/j.neuropharm.2018.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.02.022</ArticleId><ArticleId IdType="pubmed">29486168</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyao M, et al. Trinucleotide repeat length instability and age of onset in Huntington&#x2019;s disease. Nat. Genet. 1993;4:387&#x2013;392. doi: 10.1038/ng0893-387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0893-387</ArticleId><ArticleId IdType="pubmed">8401587</ArticleId></ArticleIdList></Reference><Reference><Citation>Luheshi LM, et al. Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol. 2007;5:e290. doi: 10.1371/journal.pbio.0050290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050290</ArticleId><ArticleId IdType="pmc">PMC2043051</ArticleId><ArticleId IdType="pubmed">17973577</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JN, Turnage KC, Walker CA, Lieberman RL. The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder. Biochem. 2011;50:5824&#x2013;5833. doi: 10.1021/bi200231x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi200231x</ArticleId><ArticleId IdType="pmc">PMC3128542</ArticleId><ArticleId IdType="pubmed">21612213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gieselmann V. What can cell biology tell us about heterogeneity in lysosomal storage diseases? Acta Paediatrica. 2007;94:80&#x2013;86. doi: 10.1111/j.1651-2227.2005.tb02118.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.2005.tb02118.x</ArticleId><ArticleId IdType="pubmed">15895717</ArticleId></ArticleIdList></Reference><Reference><Citation>Skorupa A, et al. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. J. Neurosci. 2012;32:5024&#x2013;5038. doi: 10.1523/JNEUROSCI.6366-11.201232/15/5024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6366-11.201232/15/5024</ArticleId><ArticleId IdType="pmc">PMC6622103</ArticleId><ArticleId IdType="pubmed">22496549</ArticleId></ArticleIdList></Reference><Reference><Citation>Luigetti M, et al. SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid progression and concomitant novel ANG variant. Neurobiol. Aging. 2011;32:1924 e1915&#x2013;1928. doi: 10.1016/j.neurobiolaging.2011.04.004S0197-4580(11)00119-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.04.004S0197-4580(11)00119-9</ArticleId><ArticleId IdType="pubmed">21621297</ArticleId></ArticleIdList></Reference><Reference><Citation>Restagno G, et al. The rare G93D mutation causes a slowly progressing lower motor neuron disease. Amyotroph. Lateral Scler. 2008;9:35&#x2013;39. doi: 10.1080/17482960701788198788218754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701788198788218754</ArticleId><ArticleId IdType="pubmed">18273717</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosio C, Casciati A, Iaccarino C, Rotilio G, Carri MT. Bcl2a1 serves as a switch in death of motor neurons in amyotrophic lateral sclerosis. Cell Death Differ. 2006;13:2150&#x2013;2153. doi: 10.1038/sj.cdd.4401943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401943</ArticleId><ArticleId IdType="pubmed">16710367</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, et al. Angiogenin promotes U87MG cell proliferation by activating NF-kappaB signaling pathway and downregulating its binding partner FHL3. PLoS One. 2015;10:e0116983. doi: 10.1371/journal.pone.0116983PONE-D-14-34157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116983PONE-D-14-34157</ArticleId><ArticleId IdType="pmc">PMC4320115</ArticleId><ArticleId IdType="pubmed">25659096</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami, N. O. et al. NF&#x2010;&#x3ba;B activation in astrocytes drives a stage&#x2010;specific beneficial neuroimmunological response in ALS. The EMBO journal37 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092622</ArticleId><ArticleId IdType="pubmed">29875132</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Agar JN, Strong MJ, Durham HD. Impaired proteasome function in sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:367&#x2013;371. doi: 10.3109/17482968.2012.686511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.686511</ArticleId><ArticleId IdType="pubmed">22632443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Agar JN, Taylor DM, Minotti S, Durham HD. Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. neurochemistry. 2004;89:1325&#x2013;1335. doi: 10.1111/j.1471-4159.2004.02453.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02453.x</ArticleId><ArticleId IdType="pubmed">15189335</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Sci. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Skorupa A, et al. Angiogenin induces modifications in the astrocyte secretome: relevance to amyotrophic lateral sclerosis. J. Proteom. 2013;91:274&#x2013;285. doi: 10.1016/j.jprot.2013.07.028S1874-3919(13)00433-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2013.07.028S1874-3919(13)00433-8</ArticleId><ArticleId IdType="pubmed">23920243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HM, Kang DK, Kim HY, Kang SS, Chang SI. Angiogenin-induced protein kinase B/Akt activation is necessary for angiogenesis but is independent of nuclear translocation of angiogenin in HUVE cells. Biochem. Biophys. Res. Commun. 2007;352:509&#x2013;513. doi: 10.1016/j.bbrc.2006.11.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.11.047</ArticleId><ArticleId IdType="pubmed">17125737</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddika S, et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J. Cell Sci. 2008;121:979&#x2013;988. doi: 10.1242/jcs.009530121/7/979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.009530121/7/979</ArticleId><ArticleId IdType="pmc">PMC2954964</ArticleId><ArticleId IdType="pubmed">18354084</ArticleId></ArticleIdList></Reference><Reference><Citation>Trouillon R, Kang DK, Park H, Chang SI, O&#x2019;Hare D. Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases. Biochem. 2010;49:3282&#x2013;3288. doi: 10.1021/bi902122w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi902122w</ArticleId><ArticleId IdType="pubmed">20235595</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2001;2:71&#x2013;81. doi: 10.1080/146608201316949415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608201316949415</ArticleId><ArticleId IdType="pubmed">11675875</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves KA, et al. Angiogenin Promotes Hematopoietic Regeneration by Dichotomously Regulating Quiescence of Stem and Progenitor Cells. Cell. 2016;166:894&#x2013;906. doi: 10.1016/j.cell.2016.06.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.06.042</ArticleId><ArticleId IdType="pmc">PMC4988404</ArticleId><ArticleId IdType="pubmed">27518564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, et al. Association between the Angiogenin (ANG) K17I variant and amyotrophic lateral sclerosis risk in Caucasian: a meta-analysis. Neurological Sci. 2015;36:2163&#x2013;2168. doi: 10.1007/s10072-015-2344-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2344-5</ArticleId><ArticleId IdType="pubmed">26255299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellera C, et al. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenet. 2008;9:33&#x2013;40. doi: 10.1007/s10048-007-0111-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-007-0111-3</ArticleId><ArticleId IdType="pubmed">18087731</ArticleId></ArticleIdList></Reference><Reference><Citation>Van EMA, et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann. Neurol. 2011;70:964&#x2013;973. doi: 10.1002/ana.22611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22611</ArticleId><ArticleId IdType="pmc">PMC5560057</ArticleId><ArticleId IdType="pubmed">22190368</ArticleId></ArticleIdList></Reference><Reference><Citation>Team, R. C. R: A language and environment for statistical computing. (2013).</Citation></Reference><Reference><Citation>Greenway MJ, et al. ANG mutations segregate with familial and &#x2018;sporadic&#x2019; amyotrophic lateral sclerosis. Nat. Genet. 2006;38:411&#x2013;413. doi: 10.1038/ng1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1742</ArticleId><ArticleId IdType="pubmed">16501576</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurol. 2009;72:287&#x2013;288. doi: 10.1212/01.wnl.0000339487.84908.0072/3/287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000339487.84908.0072/3/287</ArticleId><ArticleId IdType="pubmed">19153377</ArticleId></ArticleIdList></Reference><Reference><Citation>Seilhean D, et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. Acta Neuropathol. 2009;118:561&#x2013;573. doi: 10.1007/s00401-009-0545-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0545-9</ArticleId><ArticleId IdType="pubmed">19449021</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 2010;47:554&#x2013;560. doi: 10.1136/jmg.2010.077180jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One. 2012;7:e48983. doi: 10.1371/journal.pone.0048983PONE-D-12-26807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0048983PONE-D-12-26807</ArticleId><ArticleId IdType="pmc">PMC3498376</ArticleId><ArticleId IdType="pubmed">23155438</ArticleId></ArticleIdList></Reference><Reference><Citation>Paubel A, et al. Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2008;65:1333&#x2013;1336. doi: 10.1001/archneur.65.10.133365/10/1333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.10.133365/10/1333</ArticleId><ArticleId IdType="pubmed">18852347</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti FL, et al. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul. Disord. 2008;18:68&#x2013;70. doi: 10.1016/j.nmd.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2007.07.003</ArticleId><ArticleId IdType="pubmed">17703939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Santiago R, et al. Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J. Neurol. 2009;256:1337&#x2013;1342. doi: 10.1007/s00415-009-5124-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5124-4</ArticleId><ArticleId IdType="pmc">PMC2921066</ArticleId><ArticleId IdType="pubmed">19363631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, et al. Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. Neuropathol. Appl. Neurobiol. 2013;39:562&#x2013;571. doi: 10.1111/nan.12007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12007</ArticleId><ArticleId IdType="pmc">PMC3770927</ArticleId><ArticleId IdType="pubmed">23228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, et al. Identification of a novel missense mutation in angiogenin in a Chinese amyotrophic lateral sclerosis cohort. Amyotroph. Lateral Scler. 2012;13:270&#x2013;275. doi: 10.3109/17482968.2011.643900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.643900</ArticleId><ArticleId IdType="pubmed">22292798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>